Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(2 months from now) | |
US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(2 months from now) | |
US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(5 months from now) | |
US9259428
(Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Dec, 2023
(8 months from now) | |
US8163723
(Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(11 months from now) | |
US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(2 years from now) | |
US8168620
(Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(3 years from now) |
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis
Dosage: SPRAY, METERED;NASAL
10
United States
4
Brazil
3
Portugal
3
Spain
3
Korea, Republic of
3
Canada
3
Cyprus
3
Slovenia
3
Israel
3
Australia
3
Denmark
3
European Union
2
United Kingdom
2
New Zealand
2
Hungary
1
Germany
1
Russia
1
Costa Rica
1
Mexico
1
Austria
1
Morocco
1
China
1
Tunisia
1
South Africa
1
Luxembourg
1
Poland
1
Georgia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic